Portal de Periódicos da CAPES

Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007

2008; Oxford University Press; Volume: 30; Issue: 2 Linguagem: Inglês

10.1093/eurheartj/ehn510

1522-9645

Joost Daemen, Maarten L. Simoons, William Wijns, A Bagust, G. Bos, James M. Bowen, Eugene Braunwald, Edoardo Camenzind, B Chevalier, Carlo Di Mario, J. Fajadet, Anselm K. Gitt, Giulio Guagliumi, Hans L. Hillege, Stefan James, Peter Jüni, Adnan Kastrati, Sabine Kloth, Steen Dalby Kristensen, Mitchell W. Krucoff, Victor Legrand, Matthias Pfisterer, Martin T. Rothman, P.W. Serruys, Sigmund Silber, Philippe Gabríel Steg, I. Tariah, Lars Wallentin, Stephan Windecker, A. Aimonetti, Dominic J. Allocco, Anna Baczyńska, A Bagust, M. Berenger, G. Bos, Ashley B. Boam, James M. Bowen, Eugene Braunwald, J. Puig La Calle, Edoardo Camenzind, Gianluca Campo, Stéphane Carlier, Bernard Chevalier, Joost Daemen, Jean De Schepper, G. Di Bisceglie, Carlo Di Mario, H. Dobbels, Jean Fajadet, Andrew Farb, J.-C. Ghislain, Anselm K. Gitt, Giulio Guagliumi, S. Hellbardt, Hans L. Hillege, R. ten Hoedt, C. Isaia, Stefan James, Peter J. de Jong, Peter Jüni, Adnan Kastrati, Elizabeth Klasen, Sabine Kloth, Steen Dalby Kristensen, Mitchell W. Krucoff, Victor Legrand, Malik Lekehal, LeRoy LeNarz, Fiona Mhulláin, Hirofumi Nagai, A. Patteet, Dragica Paunovic, Matthias Pfisterer, A. Potgieter, I B Purdy, C Raveau-Landon, Martin T. Rothman, Patrick W. Serruys, Sigmund Silber, Maarten L. Simoons, Philippe Gabríel Steg, I. Tariah, S. Ternstrom, J. Van Wuytswinkel, Matthias Waliszewski, Lars Wallentin, William Wijns, Stephan Windecker,

Cardiac Valve Diseases and Treatments

Drug-eluting stents (DES) were introduced into clinical practice in 2002 in order to reduce restenosis that occurred in 15–25% of patients receiving bare-metal stents (BMS).1–3 Subsequent trials with different types of DES confirmed their efficacy in this regard.4 However, late stent thrombosis was reported as early as 2004, typically in patients discontinuing dual anti-platelet therapy.5 At the European and World Congress of Cardiology in Barcelona 2006, alarming data were presented on a worse long-term prognosis following DES implantation compared with BMS.6,7 As a result both randomized controlled trials and registry data were scrutinized to validate these concerns, bearing in mind the differential values of both types of studies.8,9 Furthermore, the worldwide discussion on the long-term safety and efficacy of DES triggered the European Society of Cardiology together with the European Association for Percutaneous Cardiovascular Interventions to organize a forum on DES. On 27 and 28 September 2007, key opinion leaders in (interventional) cardiology and representatives from industry and regulatory bodies gathered in the European Heart House with the intention to review: (i) the most recent data on the long-term efficacy (reduction of restenosis, re-intervention) and safety (late stent thrombosis, myocardial infarction, mortality) of DES and its effects on outcome (survival, event-free survival), (ii) specific indications for DES; (iii) health economical analyses currently performed with DES; (iv) the DES registration process in Europe; (v) current and possible future trial designs. The overall goal was to provide general recommendations to the medical community for the use, clinical development, and future assessment of DES. In several randomized controlled trials comparing sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) and BMS, increased rates of death or myocardial infarction were observed at follow-up, beyond the first year,6–8,10 while no excess …